Livzon Pharmaceutical Group (SZSE:000513) EBIT : ¥2,594 Mil (TTM As of Mar. 2024)

View and export this data going back to 1993. Start your Free Trial

What is Livzon Pharmaceutical Group EBIT?

Livzon Pharmaceutical Group's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was ¥867 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥2,594 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Livzon Pharmaceutical Group's annualized ROC % for the quarter that ended in Mar. 2024 was 25.03%. Livzon Pharmaceutical Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 75.38%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Livzon Pharmaceutical Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 10.51%.

Livzon Pharmaceutical Group EBIT Historical Data

The historical data trend for Livzon Pharmaceutical Group's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Livzon Pharmaceutical Group EBIT Chart

Livzon Pharmaceutical Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

1,734.80

2,514.75

2,329.69

2,428.10

2,484.75

Livzon Pharmaceutical Group Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															758.08	713.98	572.73	439.96	867.24

Competitive Comparison of Livzon Pharmaceutical Group's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Livzon Pharmaceutical Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Livzon Pharmaceutical Group's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Livzon Pharmaceutical Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Livzon Pharmaceutical Group's EV-to-EBIT falls into.

Livzon Pharmaceutical Group EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥2,594 Mil.

Livzon Pharmaceutical Group (SZSE:000513) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Livzon Pharmaceutical Group's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	3146.196 * ( 1 - 15.2% )	/	( (10486.204	+	10834.992)	/ 2 )
=	2667.974208	/	10660.598
=	25.03 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	25044.827	-	5379.585	-	( 11407.516	-	max(0, 8087.137	-	17266.175	+	11407.516	))
=	10486.204

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	25189.696	-	5506.404	-	( 11231.003	-	max(0, 8329.92	-	17178.22	+	11231.003	))
=	10834.992

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Livzon Pharmaceutical Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	3468.972	/	( ( (4604.447 + max(-1200.13, 0))	+	(4599.478 + max(-1266.938, 0)) )	/	2 )
=	3468.972	/	( ( 4604.447	+	4599.478 )	/	2 )
=	3468.972	/	4601.9625
=	75.38 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(2115.659	+	2060.651	+	191.008)	-	(5379.585	+	0	+	187.863)
=	-1200.13

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(2067.187	+	2015.39	+	280.53)	-	(5506.404	+	0	+	123.641)
=	-1266.938

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Livzon Pharmaceutical Group's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	2593.911	/	24690.332
	=	10.51 %

Livzon Pharmaceutical Group EBIT Related Terms

Thank you for viewing the detailed overview of Livzon Pharmaceutical Group's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Livzon Pharmaceutical Group (SZSE:000513) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Livzon Pharmaceutical Group Inc (SZSE:000513) » Definitions » EBIT

Traded in Other Exchanges

01513:Hong Kong LP6:Germany

Address

38 Chuangye North Road, Headquarters Building, Jinwan District, Guangdong Province, Zhuhai, CHN, 519090

Website

https://www.livzon.com.cn

Livzon Pharmaceutical Group Inc is engaged in China's healthcare sector. As a pharmaceutical manufacturer, the company's portfolio comprises Western pharmaceutical preparations, bulk drugs, traditional Chinese medicines, as well as diagnostic reagents and equipment. Its drug address serious conditions such as gastrointestinal, cardiovascular, anti-infectious, antimicrobial, antineoplastic, hemopoietic system, and other conditions. It distributes its products within domestic markets and to overseas markets. It operates in a single reportable segment which is pharmaceutical manufacturing.

Livzon Pharmaceutical Group (SZSE:000513) Headlines

No Headlines